Supercharged immune cells take on Hard-to-Treat pancreatic cancer
NCT ID NCT07145450
First seen Jun 21, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-stage trial tests a new type of immunotherapy for people with advanced pancreatic cancer that has spread or cannot be removed. The treatment uses a patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells carrying specific KRAS mutations. Up to 96 adults will receive a single infusion of these engineered cells, along with chemotherapy to prepare the body. The study aims to find a safe dose and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PDAC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC - VU Medical Center
RECRUITINGAmsterdam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité Universitätsmedizin Berlin
RECRUITINGBerlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Herlev and Gentofte University Hospital
RECRUITINGCopenhagen, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karolinska University Hospital
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen - Campus Grosshadern - Medizinische Klinik und Poliklinik III
NOT_YET_RECRUITINGMünchen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Radboud University Medical Center
RECRUITINGNijmegen, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus
RECRUITINGDresden, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitaetsklinikum Heidelberg
RECRUITINGHeidelberg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitaetsklinikum Leipzig - Universitaeren Krebszentrum (UCCL)
NOT_YET_RECRUITINGLeipzig, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital and Faculty of Medicine Eberhard Karls University Tübingen
RECRUITINGTübingen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (TCR-T cells) targeting specific KRAS mutations
What this could lead to
If successful, this could lead to a new treatment option for advanced pancreatic cancer patients with specific KRAS mutations, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early first-in-human trial with only 96 participants, so safety and effectiveness are not yet proven. There are risks of severe side effects from the chemotherapy and the cell therapy itself, and the treatment may not work for everyone.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.